Humans are not doing enough to mitigate climate change effects that are already inevitable, the world’s climate scientists […]

There is an enormous difference between being a doctor and being the family doctor, as Mathew expounds,1 and […]

A $26bn payout in a US legal case pitting opioid makers and distributors against thousands of local governments […]

Lung safety review delays FDA decision on United’s Tyvaso DPI ntaylor Tue, 03/01/2022 – 09:40

CTI BioPharma clinches long-awaited FDA approval for myelofibrosis blockbuster prospect Vonjo fkansteiner Tue, 03/01/2022 – 09:57

With Bayer’s new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long? aliu […]

Gilead’s HIV prospect lenacapavir hits FDA approval snag amid vial compatibility concerns fkansteiner Tue, 03/01/2022 – 10:48

FibroGen’s roxadustat safety mess draws SEC scrutiny as AstraZeneca-partnered anemia drug remains in limbo aliu Tue, 03/01/2022 – […]

The government needs to get tougher on public health and put more focus on interventions at the population […]

Appleby has picked up something of a poisoned chalice in predicting GP workforce requirements.1 His article appears in […]